Abstract
Entinostat is a synthetic benzamide derivative histone deacetylase (HDAC) inhibitor, which potently and selectively inhibits class I and IV HDAC enzymes. This action promotes histone hyperacetylation and transcriptional activation of specific genes, with subsequent inhibition of cell proliferation, terminal differentiation and apoptosis. This oral HDAC inhibitor has been evaluated in Phase I and II trials in patients with advanced malignancies, and is in general well tolerated. Entinostat does not currently have regulatory approval for clinical use; however promising preclinical and clinical data exist in hormone-resistant breast cancer. An ECOG-ACRIN Phase III registration study is ongoing in advanced breast cancer (E2112, NCT02115282) and aims to confirm the overall survival advantage observed with the combination of exemestane and entinostat/placebo in the Phase II setting (ENCORE301 trial). This article provides an overview of the chemistry, pharmacokinetics/pharmacodynamics and available clinical data for entinostat with a focus on advanced breast cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1137-1148 |
| Number of pages | 12 |
| Journal | Future Oncology |
| Volume | 13 |
| Issue number | 13 |
| DOIs | |
| State | Published - Jun 2017 |
Keywords
- breast cancer
- clinical trials
- entinostat
- epigenetics
- histone deacetylase inhibitor
ASJC Scopus subject areas
- Oncology
- Cancer Research